AlphaRx Inc. (OTC BB: ALRX), a specialty pharmaceutical company announced that its ARX828, an orally-administered, potent and selective inhibitor of iNOS (Inducible Nitric Oxide Synthase), is advancing to preclinical studies to support an investigational new drug (IND) application in 2008.
In animal models of inflammation, the anti-inflammatory activity of ARX828 is significantly higher than Indomethacin and as effective as Dexamethasone (a steroidal drug), but without the side-effects associated with either of these drugs.
The Company has initiated two pivotal animal studies for ARX828 and expects to receive results from these studies for analysis, by end of November. The Company's goal is to develop ARX828 for the treatment of Rheumatoid Arthritis and Inflammatory Bowel Disease.
About Rheumatoid Arthritis (RA)
There is no treatment currently available to cure RA. The goals of treatment are to relieve pain, reduce inflammation, slow down joint damage and improve function. Most RA patients require some form of DMARD--these include methotrexate, an anti-cancer agent or the TNF-blocking agents such as Enbrel. The TNF-blocking agents only inhibit the inflammatory mediator, TNF, and require parenteral administration.
Good things are coming our way.
LEV
I feel better, I am just so concerned about the side effects of the drugs i do take. You know, methotrexate kills fast growing cells such as cancer cells. The problem is that skin cells are fast growing cells. Bone and marrow are fast growing cells. stomach and intestines linings are fast growing cells etcs and etcs and bla bla blahs. I want drugs with-out the bad extra baggage and i'm sure you all know what i mean.
LEV